Summary
LTF-SM is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed through structural modifications of the native GLP-1 hormone. It is one of the foundational reference compounds in modern incretin-pharmacology literature.
Overview
LTF-SM differs from native GLP-1 by amino-acid substitutions at positions 8 and 34 and by a fatty-acid side chain at position 26 that promotes albumin binding. The albumin-binding modification dramatically extends its functional half-life relative to native GLP-1.
Research Background
LTF-SM was developed at Novo Nordisk and described in the discovery literature by Knudsen, Lau, and colleagues (2019). The compound is the result of a structure-activity program building on the earlier GLP-1 analog liraglutide, with the goal of producing a once-weekly long-acting incretin reference compound.
Mechanisms Studied
Mechanistic interest centers on its full-agonist activity at the GLP-1 receptor, the structural basis for its extended half-life through albumin binding, and the downstream cAMP signaling that follows receptor activation. Comparative-pharmacology work has examined how LTF-SM differs from earlier and later compounds in the same research lineage.
Published Research Summary
Knudsen and Lau (2019) describe the discovery and development of LTF-SM alongside liraglutide. Lau et al. (2015) describe the original LTF-SM structure-activity work. Comparative pharmacology against LTF-TZ (Coskun 2018) and LTF-RT (Coskun 2022) is summarized in the GLP-1 comparison guide on this site.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.